follicular lymphoma

August 20, 2019

Clinical Trials in China Will Test Abexinostat for DLBCL, Follicular Lymphoma

News

Xynomic Pharma is launching two pivotal clinical trials in China to test its investigational HDAC inhibitor, abexinostat, as a third-line therapy for two types of non-Hodgkin’s lymphoma: diffuse large B-cell lymphoma (DLBCL) and follicular ... Read more

August 16, 2019August 14, 2019

Finding My ‘Big Lymphoma Family’

Columns, Things That Give Me Hope - a Column by Bob McEachern

Cancer has a way of isolating us. Friends and family can be supportive, but sometimes they don’t understand what you’re going through. I have found that it helps to think ... Read more

August 9, 2019September 9, 2019

Cerdulatinib Alone or with Rituxan Effective in Previously Treated Follicular Lymphoma, Data Show

News

Treatment with the oral therapy cerdulatinib alone or in combination with Rituxan (rituximab) shows durable efficacy, including some complete responses, in patients with follicular lymphoma who failed prior medications, according ... Read more

August 8, 2019September 10, 2019

FDA Asked to Place Abexinostat, Possible Follicular Lymphoma Treatment, on Fast Track

News

Xynomic Pharmaceuticals has filed a request with U.S. Food and Drug Administration (FDA) asking that abexinostat, its lead therapeutic candidate for relapsed or refractory follicular lymphoma, be given fast track designation. The ... Read more

July 9, 2019

REGN1979 Eliminated Cancer in Most Non-Hodgkin’s Lymphoma Patients in Phase 1 Trial

News

Regeneron‘s bispecific antibody REGN1979 is showing outstanding clinical effectiveness in B-cell non-Hodgkin’s lymphoma patients who received prior treatments, including those who progressed after CAR T-cell therapies. The treatment completely eliminated ... Read more

June 25, 2019

Zanubrutinib-Gazyva Shows Promise for CLL/SLL, Follicular Lymphoma

News

Zanubrutinib in combination with Gazyva (obinutuzumab) leads to clinically meaningful responses and is well-tolerated by patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma, a Phase 1b trial ... Read more

June 14, 2019

ME-401 Experimental Compound Reduces Tumor Burden in Follicular Lymphoma, Phase 1 Trial Shows

News

MEI Pharma‘s experimental compound ME-401 reduced tumor burden in 80% of patients with relapsed or refractory follicular lymphoma in a Phase 1 trial, the company said. Responses were comparable among ... Read more

April 5, 2019

Three-tiered Combination Stimulates Immune System to Attack Lymphoma Cells, Phase 1/2 Trial Shows

News

A combination of oral Imbruvica (ibrutinib), intratumoral CpG, and local low-dose radiation stimulates the immune system to safely and effectively attack lymphoma cells, according to a new study. The study, ... Read more

March 28, 2019

Revlimid/Rituxan Combo Shows Promise in Follicular, Marginal Zone Lymphomas

News

Patients with follicular lymphoma and marginal zone lymphoma who failed at least one prior therapy live significantly longer — more than two years — without their disease worsening when treated with a combination ... Read more

March 8, 2019March 7, 2019

The Thing with Feathers: Holding On to Hope for a Cancer Cure

Columns, Things That Give Me Hope - a Column by Bob McEachern

My daughter’s high school English class is reading a poem by Emily Dickinson. It begins with: “’Hope’ is the thing with feathers.” I read the poem in high school, too. ... Read more